Lo YM - Search Results

1

Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA.

Chan AT, Ma BB, Lo YM, Leung SF, Kwan WH, Hui EP, Mok TS, Kam M, Chan LS, Chiu SK, Yu KH, Cheung KY, Lai K, Lai M, Mo F, Yeo W, King A, Johnson PJ, Teo PM, Zee B. Chan AT, et al. Among authors: lo ym. J Clin Oncol. 2004 Aug 1;22(15):3053-60. doi: 10.1200/JCO.2004.05.178. J Clin Oncol. 2004. PMID: 15284255 Clinical Trial.

2

Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma.

Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YM. Lei KI, et al. Among authors: lo ym. Clin Cancer Res. 2002 Jan;8(1):29-34. Clin Cancer Res. 2002. PMID: 11801537

3

Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas.

Zhong S, Tang MW, Yeo W, Liu C, Lo YM, Johnson PJ. Zhong S, et al. Among authors: lo ym. Clin Cancer Res. 2002 Apr;8(4):1087-92. Clin Cancer Res. 2002. PMID: 11948118

4

Plasma nucleic acids in the diagnosis and management of malignant disease.

Johnson PJ, Lo YM. Johnson PJ, et al. Among authors: lo ym. Clin Chem. 2002 Aug;48(8):1186-93. Clin Chem. 2002. PMID: 12142371 Review.

5

Presence of filterable and nonfilterable mRNA in the plasma of cancer patients and healthy individuals.

Ng EK, Tsui NB, Lam NY, Chiu RW, Yu SC, Wong SC, Lo ES, Rainer TH, Johnson PJ, Lo YM. Ng EK, et al. Among authors: lo ym, lo es. Clin Chem. 2002 Aug;48(8):1212-7. Clin Chem. 2002. PMID: 12142376

6

Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma.

Chan AT, Lo YM, Zee B, Chan LY, Ma BB, Leung SF, Mo F, Lai M, Ho S, Huang DP, Johnson PJ. Chan AT, et al. Among authors: lo ym. J Natl Cancer Inst. 2002 Nov 6;94(21):1614-9. doi: 10.1093/jnci/94.21.1614. J Natl Cancer Inst. 2002. PMID: 12419787

7

Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma.

Chan KC, Lo YM. Chan KC, et al. Among authors: lo ym. Semin Cancer Biol. 2002 Dec;12(6):489-96. doi: 10.1016/s1044579x02000913. Semin Cancer Biol. 2002. PMID: 12450734 Review.

8

Quantitative analysis of pleural fluid cell-free DNA as a tool for the classification of pleural effusions.

Chan MH, Chow KM, Chan AT, Leung CB, Chan LY, Chow KC, Lam CW, Lo YM. Chan MH, et al. Among authors: lo ym. Clin Chem. 2003 May;49(5):740-5. doi: 10.1373/49.5.740. Clin Chem. 2003. PMID: 12709364

9

Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients.

Chan KC, Zhang J, Chan AT, Lei KI, Leung SF, Chan LY, Chow KC, Lo YM. Chan KC, et al. Among authors: lo ym. Cancer Res. 2003 May 1;63(9):2028-32. Cancer Res. 2003. PMID: 12727814

10

Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.

Leung SF, Chan AT, Zee B, Ma B, Chan LY, Johnson PJ, Lo YM. Leung SF, et al. Among authors: lo ym. Cancer. 2003 Jul 15;98(2):288-91. doi: 10.1002/cncr.11496. Cancer. 2003. PMID: 12872347 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

499 results

Search Page

Filters